**Lack of Tocilizumab effect on mortality in COVID19 patients**

Gregory E Holt1, Mayank Batra1, Mukunthan Murthi1, Shweta Kambali1, Kayo Santos1, Maria Virginia Perez Bastidas1, Huda Asif1, Sara Hadadi1, Sixto Arias1, and Mehdi Mirsaeidi1

1Division of Pulmonary and Critical Care, University of Miami, Miami, FL, USA

Table 1. Sociodemographic and clinical variables of subjects with COVID19

|  |  |  |  |
| --- | --- | --- | --- |
| Demographics (N = 62) | Survived N(%) | Did not Survive N(%) | P-Value |
| Age, mean (SD) (years) | 60.33(12.5) | 74.16(11.4) | <0.001 |
| Age≥ 75 (N = 15) | 5 (11.6) | 10 (52.6) | 0.001 |
| Male (N = 44) | 30 (69.8) | 14 (73.7) | 0.754 |
| Hispanics (N=34) | 23(56.1) | 11(64.7) | 0.545 |
| White (N = 33) | 20(51.3) | 13(76.5) | 0.085 |
| Black (N = 15) | 13(33.3) | 2(11.8) | 0.109 |
| Asian (N = 2) | 1(2.6) | 1(5.9) | 0.55 |
| More than one race (N = 6) | 5(12.8) | 1(5.9) | 0.452 |
| Tobacco cigarette use (N = 39) | 27(62.8 | 12(63.2) | 0.978 |
| Vaping (N = 51) | 37(86) | 14(73.7) | 0.247 |
| Alcohol (N = 50) | 35(81.4) | 15(78.9) | 0.822 |
| Marijuana (N = 49) | 32(74.4) | 17(89.5) | 0.194 |
| Symptoms at or after 48 hours of hospital admission |  |  |  |
| Temperature >=100o F (N = 26) | 18(41.9) | 8(42.1) | 0.986 |
| Cough (N = 44) | 32(76.2) | 12(66.7) | 0.447 |
| Sore throat (N = 2) | 1(2.4) | 1(5.6) | 0.553 |
| Rhinorrhea (N = 4) | 3(7.3) | 1(6.3) | 0.887 |
| Dyspnea (N = 43) | 30(69.8) | 13(68.4) | 0.916 |
| Fever (N =42) | 29(67.4) | 13(72.2) | 0.713 |
| Chills (N = 21) | 13(31) | 8(44.4) | 0.318 |
| Myalgias (N = 16) | 10(24.4) | 6(33.3) | 0.478 |
| Abdominal pain (N = 5) | 4(9.8) | 1(5.9) | 0.636 |
| Diarrhea (N = 5) | 3(7.3) | 2(11.1) | 0.632 |
| Nausea/vomiting (N = 7) | 5(12.2) | 2(11.8) | 0.963 |
| Altered mental status (N = 8) | 3(7.1 | 5(29.4) | 0.035 |
| Pre-admission oxygen use (N = 5) | 1(2.4) | 4(21.1) | 0.039 |
| Inhaled steroid use (N = 6) | 4(9.5) | 2(11.1) | 0.851 |
| qSOFA, mean (SD) | 0.4(0.5) | 0.7(0.7) | 0.145 |
| Medications prior to hospital admission |  |  |  |
| Prednisone | 6(14.3) | 2(11.1) | 0.741 |
| ACE inhibitors | 4(9.5) | 3(17.6) | 0.389 |
| Angiotensin Receptor Blockers | 7(16.7) | 3(17.6) | 0.928 |
| Statins | 10(23.8) | 7(41.2) | 0.187 |
| Emergency Room visit within 12 months | 10(24.4) | 4(22.2) | 0.857 |
| Hospital admission within last 12 months | 11(26.8) | 5(27.8) | 0.94 |
| Nursing home/long term care facility residents | 5(11.9) | 9(47.4) | 0.004 |
| Findings at Chest X-Ray or CT images obtained while in hospital |  |  |  |
| Ground glass opacities | 9(22.0) | 5(26.3) | 0.71 |
| Consolidations | 10(24.4) | 8(42.1) | 0.168 |
| Pleural effusions | 5(12.2) | 5(26.3) | 0.181 |
| Bilateral infiltrates | 27(65.9) | 19(31.7) | 0.552 |
| Comorbidities |  |  |  |
| Chronic Obstructive Pulmonary Disease | 4(9.5) | 1(5.3) | 0.58 |
| Supportive oxygen before admission | 16(42.1 | 13(68.4) | 0.066 |
| Congestive Heart Failure | 1(2.4) | 2(10.5) | 0.211 |
| Atrial fibrillation | 4(9.5) | 2(10.5) | 0.903 |
| Hypertension | 23(54.8) | 14(73.7) | 0.167 |
| Stroke | 4(9.5) | 2(10.5) | 0.903 |
| Dementia | 2(4.8) | 1(5.3) | 0.933 |
| Chronic Renal Failure | 2(4.8) | 1(5.3) | 0.933 |
| Diabetes Mellitus | 10(23.8) | 13(68.4) | 0.02 |
| Lymphoma | 2(4.8) | 1(5.3) | 0.933 |
| Solid tumor | 1(2.4) | 4(21.1) | 0.039 |
| Laboratory findings at or within 48 hours of admission to hospital |  |  |  |
| Procalcitonin ≥ 1.15 ng/mL | 7(16.3 | 5(26.3) | 0.36 |
| Fibrinogen ≥ 649 mg/dL | 2(4.7) | 1(5.3) | 0.918 |
| IL-6 > 580 pg/mL | 1(2.3) | 4(21.1) | 0.037 |
| IL-6 > 580pg/mL, mean (SD) | 177.9(227.6) | 1384.2(1234.7) | 0.028 |
| Ferritin > 1631ng/mL | 6(14.0) | 7(36.8) | 0.048 |
| C-Reactive Protein ≥ 21 | 7(16.3) | 6(31.6) | 0.179 |
| Mechanical ventilation use | 21(65.6) | 15(83.3) | 0.19 |
| Positive blood culture obtained after tocilizumab | 5(16.1) | 2(11.8) | 0.683 |
| Medications for COVID19 |  |  |  |
| Tocilizumab | 22(51.2) | 10(52.6) | 0.915 |
| Tocilizumab administration post-admission, mean (SD) (days) | 2.6(1.7) | 5.2(9.4) | 0.414 |
| Tocilizumab for more than 4 days | 6(14.0) | 2(10.5) | 0.711 |
| Chloroquine/Hydroxychloroquine | 31(72.1 | 15(32.6) | 0.571 |
| Macrolides | 33(76.7) | 16(84.2) | 0.508 |
| Steroids | 26(60.5) | 10(52.6) | 0.565 |
| Outcome |  |  |  |
| Hospital stay duration, mean (SD) day | 25.4(17.1) | 16.4(13.2) | 0.046 |
| ICU stay duration, mean (SD) day | 11.4(15.6) | 10.5(11.0) | 0.833 |
| Patient delay\*, mean (SD) day | 5.3(4.8) | 3.9 (3.2) | 0.394 |
| Physician delay\*\*, mean (SD) day | 5.3(5.3) | 4.0(4.0) | 0.437 |
| Readmission | 3(7.0) | 1(5.3) | 0.801 |
| ICU admission | 29(67.4) | 17(89.5) | 0.083 |

A screenshot of a cell phone

Description automatically generated

Figure 1. Forest plot showing the variables used in the multivariate model among COVID19 subjects. Hosmer lameshow score>0.05, IL6 and Ferritin units: pg/ml.